Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity

Cells. 2022 Oct 6;11(19):3147. doi: 10.3390/cells11193147.

Abstract

In recent years, immunotherapy has become a powerful therapeutic option against multiple malignancies. The unique capacity of natural killer (NK) cells to attack cancer cells without antigen specificity makes them an optimal immunotherapeutic tool for targeting tumors. Several approaches are currently being pursued to maximize the anti-tumor properties of NK cells in the clinic, including the development of NK cell expansion protocols for adoptive transfer, the establishment of a favorable microenvironment for NK cell activity, the redirection of NK cell activity against tumor cells, and the blockage of inhibitory mechanisms that constrain NK cell function. We here summarize the recent strategies in NK cell-based immunotherapies and discuss the requirement to further optimize these approaches for enhancement of the clinical outcome of NK cell-based immunotherapy targeting tumors.

Keywords: NK cell-based therapy; antibody-based therapeutics; cancer immunotherapy; cytokine therapy; innate immunity; natural killer cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer
  • Humans
  • Immunotherapy* / methods
  • Killer Cells, Natural
  • Neoplasms* / pathology
  • Tumor Microenvironment

Grants and funding

M.A. is funded by the Spanish Association Against Cancer’s Investigator grant (INVES19041ALVA). A.M. is supported by Ministero dell’Istruzione (MIUR): FISR2020IP_02937. K.M. reports receiving funding from ImaginAb, Xilio, Iovance, Checkpoint Pharmaceuticals, Werewolf, InsTIL, and Sanofi. I.M. reports receiving commercial research grants from BMS, Highlight Therapeutics, Alligator, Pfizer Genmab, and Roche.